Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hypochondroplasia Clear all
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Hypochondroplasia
Interventions
Vosoritide, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
0 Months to 36 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced May 21, 2026, 7:39 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Hypochondroplasia
Interventions
Vosoritide, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
3 Years to 17 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Wilmington, Delaware • Washington D.C., District of Columbia • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced May 21, 2026, 7:39 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Short Stature
Interventions
Vosoritide
Drug
Lead sponsor
Andrew Dauber
Other
Eligibility
3 Years to 10 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2035
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced May 21, 2026, 7:39 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Hypochondroplasia
Interventions
Not listed
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
30 Months to 16 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced May 21, 2026, 7:39 PM EDT
Enrolling by invitation Phase 3 Interventional
View directory record Official record
Conditions
Hypochondroplasia
Interventions
Vosoritide
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
Not listed
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
4
States / cities
Wilmington, Delaware • Washington D.C., District of Columbia • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced May 21, 2026, 7:39 PM EDT
Enrolling by invitation Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Hypochondroplasia
Interventions
infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
3 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced May 21, 2026, 7:39 PM EDT
Enrolling by invitation Phase 2 Interventional
View directory record Official record
Conditions
Hypochondroplasia
Interventions
Infigratinib
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
3 Years to 18 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
8
States / cities
Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced May 21, 2026, 7:39 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Hypochondroplasia
Interventions
Not listed
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
Up to 15 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2043
U.S. locations
16
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced May 21, 2026, 7:39 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Achondroplasia, Hypochondroplasia
Interventions
Not listed
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
3 Months and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced May 21, 2026, 7:39 PM EDT